Antibiotice
Antibiotice is a Romanian pharmaceutical manufacturer founded in 1955, producing over 165 generic medicines across 8 GMP-certified production flows, with FDA approvals enabling US exports, and serving hospitals, pharmacies, and public health systems in 70+ countries.
- Company typePublic
- Founded1955
- HeadquartersValea Lupului, Romania
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Antibiotice firmographics
Firmographics- Name
- Antibiotice
- Legal name
- S.C. ANTIBIOTICE S.A.
- Website
- https://antibiotice.ro
- Company type
- Public
- Founded year
- 1955
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Antibiotice is a Romanian pharmaceutical manufacturer founded in 1955, producing over 165 generic medicines across 8 GMP-certified production flows, with FDA approvals enabling US exports, and serving hospitals, pharmacies, and public health systems in 70+ countries.
- Ownership category
- akta.pro rank
Antibiotice industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Sterile Injectable Generics (HLAIABAC), Generic Hospital & Institutional Products (HLAIABAL), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)
Keywords
Where Antibiotice is headquartered
LocationHeadquarters
- HQ city
- Valea Lupului
- HQ country
- Romania
- HQ region
- Europe
Offices2 records
Markets served
Antibiotice business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Generic Pharmaceutical Products: Antibiotice manufactures and sells generic medicines including prescription (RX) and over-the-counter (OTC) products. Portfolio includes over 165 medicines covering therapeutic areas such as anti-infectives, cardiovascular, oncology, central nervous system, and quality of life prophylaxis. Products are sold domestically in Romania and exported to 70+ countries worldwide through direct sales, distributors, and international tenders.
- Veterinary Products: Production and sale of veterinary medicinal products including prescription veterinary products and the VetAria+ product line.
- Active Pharmaceutical Ingredients: Manufacture and supply of active pharmaceutical ingredients including Nystatin, which is supplied to international partners.
- Contract Manufacturing: The company offers contract manufacturing services for pharmaceutical products under GMP conditions.
- Cosmetics and Medical Devices: Production and sale of cosmetic products and medical devices as part of diversified product portfolio.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Pharmaceutical products - quote-based institutional pricing |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
Antibiotice product offering
Product offeringCore offering
Antibiotice manufactures and distributes a broad portfolio of generic pharmaceutical products, including human prescription (RX) and over-the-counter (OTC) medicines, veterinary products, active pharmaceutical ingredients, nutritional supplements, cosmetics, medical devices, biocides, and microbial biostimulators. The company operates 8 GMP-certified production flows at its Iași industrial platform and exports to over 70 countries. It also offers contract manufacturing services under GMP conditions for third-party pharmaceutical products.
Product overview
Antibiotice is a Romanian pharmaceutical company that manufactures and distributes a broad portfolio of generic medicines. The company operates eight GMP-certified production flows and produces human medicines (prescription and OTC), veterinary products (VetAria+), nutritional supplements (Nutriensa), active pharmaceutical ingredients, cosmetic products, medical devices, biocides, and microbial biostimulators. The portfolio covers therapeutic areas including anti-infectives, cardiovascular, oncology, and central nervous system medications. The company also offers contract manufacturing services and exports to over 70 countries worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- VetAria+: Veterinary product line brand
- Nutriensa
- Zifelle
- a+ Oxy
- a+ Complex Solution
Products and services
- Prescription Human Medicines (RX) Prescription pharmaceutical products for human use covering therapeutic areas including anti-infectives, cardiovascular, oncology, and central nervous system; supplied to hospitals, pharmacies, and government health systems domestically and internationally.
- Over-the-Counter Medicines (OTC)
Quantifiable outcome
- Over 165 medicines in portfolio covering multiple therapeutic areas
- +6 more outcomes
Companies that use Antibiotice
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
Antibiotice technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature4 records
Antibiotice partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, strategic and minor.
- United Nations Global Compact (UNGC)coreIn June 2025, Antibiotice became a member of the UN Global Compact, the world's largest corporate sustainability initiative. Through this affiliation, the company commits to upholding the Ten Principles of the UNGC on human rights, labor standards, environmental protection, and anti-corruption, and aligns operations with the 17 UN Sustainable Development Goals.
- Science Based Targets initiative (SBTi)coreIn 2025, Antibiotice joined SBTi, committing to set carbon reduction targets aligned with the 1.5°C global warming pathway. Once officially validated by SBTi, the company will publish its decarbonization objectives and plans, ensuring transparency and accountability.
- Romanian Sustainability CoalitionstrategicSince 2023, Antibiotice has been a member of the Romanian Sustainability Coalition supported by the Embassy of Sustainability and the Department for Sustainable Development within the Government of Romania. Through this partnership, the company supports Sustainable Development Goals focused on health and well-being, clean energy, and climate action. The Coalition brings together 173 organizations.
- Alexandru Ioan Cuza University IașistrategicTraditional collaboration partnership with the Faculty of Chemistry and Faculty of Biology for student recruitment, internships, and talent development in pharmaceutical sciences.
- Grigore T. Popa University of Medicine and Pharmacy IașistrategicPartnership with Faculty of Pharmacy and Bioengineering for talent recruitment, internships, and joint master's programs. In 2024, launched new master's programs in Pharmaceutical Safety Assessment and Regulatory Affairs.
- Gheorghe Asachi Technical University IașistrategicPartnership with Faculty of Chemical Engineering and Environmental Protection for student recruitment and practical training in pharmaceutical manufacturing.
- Regional Center for Blood Transfusion IașiminorPartnership for organizing biannual mobile blood donation campaigns. Antibiotice employees have participated since 2010 in blood donation campaigns organized in partnership with the center.
- Petru Poni Technological High SchoolminorPartnership for vocational training and dual education programs in the pharmaceutical field.
- Carol I High School IașiminorEducational partnership for student engagement and career orientation in pharmaceutical industry.
- EcoVadisstrategicThird-party sustainability assessment provider. Antibiotice achieved Gold Medal (Top 5%, 98th percentile globally) in 2026 EcoVadis assessment with a score of 85/100.
- SustainalyticsstrategicESG assessment provider collaborating with Bucharest Stock Exchange. Antibiotice has participated in ESG assessment program since 2021.
Scale indicators11 records
Recent moves9 records
Expansion highlights6 records
Antibiotice competitors and assessment
Company assessmentDirect peers
- Zentiva: Pan-European generic pharmaceutical manufacturer headquartered in Prague with broad portfolio across therapeutic areas and 30+ country footprint. Closely comparable to Antibiotice as a mid-sized European generic manufacturer with EU tender exposure and Eastern European production base.
- Krka: Slovenian generic pharmaceutical manufacturer with vertically integrated API and finished-dose production, exporting to 70+ countries. Highly comparable to Antibiotice in scale, geographic model, and portfolio breadth across prescription generics, veterinary, and consumer health.
- Gedeon Richter: Hungarian pharmaceutical company with strong generic and specialty pharma portfolio across Central/Eastern Europe and international markets. Comparable as a regional Central/Eastern European pharma manufacturer with EU regulatory footprint and similar institutional customer base.
- Polpharma: Polish pharmaceutical manufacturer producing generics, APIs, and OTC products across Eastern and Central Europe. Directly comparable in therapeutic areas, manufacturing model, and Eastern European institutional customer base.
- Alvogen: US-headquartered generic pharmaceutical company with strong Central/Eastern European manufacturing presence and emerging-market focus. Comparable as a mid-sized generic manufacturer with international tender exposure and similar geographic profile to Antibiotice.
Broad incumbents
- Stada Arzneimittel: Large German-headquartered European generic pharmaceutical and consumer healthcare company with extensive EU tender footprint. Comparable in product categories (generics, OTC, specialty) and institutional customer mix, though larger and more diversified geographically.
- Hikma Pharmaceuticals: UK-headquartered multinational pharmaceutical company with strong generics, injectables, and branded portfolio across MENA, Europe, and the US. Comparable through injectable generics manufacturing, FDA-approved operations, and public tender expertise similar to Antibiotice.
- Sandoz: Global generic and biosimilar pharmaceutical company spun off from Novartis, with broad EU and US generic portfolio. Comparable as an FDA-approved sterile injectable manufacturer and EU tender supplier, though substantially larger and more global than Antibiotice.
- Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive portfolio across all major therapeutic areas and global EU/US tender participation. Comparable in core generic manufacturing and FDA-approved operations, though vastly larger and more diversified.
- Viatris: Global healthcare company formed via Mylan-Upjohn merger, with strong generic, biosimilar, and branded portfolio across 165+ countries. Comparable geographic breadth (Antibiotice reaches 70+ countries), generic injectables, and FDA-approved manufacturing footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Antibiotice social profiles
Digital presenceAntibiotice compliance and trust
Trust signalCompliance9 records
Antibiotice financial estimates
Financial estimateRevenue estimate
Valuation estimate
Antibiotice leadership team
Management profileNumber of profiles
Profiles1 record
Antibiotice funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Antibiotice M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Antibiotice
What does Antibiotice do?
Antibiotice manufactures and distributes a broad portfolio of generic pharmaceutical products, including human prescription (RX) and over-the-counter (OTC) medicines, veterinary products, active pharmaceutical ingredients, nutritional supplements, cosmetics, medical devices, biocides, and microbial biostimulators. The company operates 8 GMP-certified production flows at its Iași industrial platform and exports to over 70 countries. It also offers contract manufacturing services under GMP conditions for third-party pharmaceutical products.
Is Antibiotice a public or private company?
Antibiotice is a public company. It is classified as public and is currently operating.
When was Antibiotice founded?
Antibiotice was founded in 1955. It employs 1,001 to 5,000 people.
Where is Antibiotice based?
Antibiotice is headquartered in Valea Lupului, Romania, in the Europe region.
How does Antibiotice make money?
Five revenue lines are on record. Generic Pharmaceutical Products are the primary driver. The others are veterinary Products, active Pharmaceutical Ingredients, contract Manufacturing and cosmetics and Medical Devices.
Who are Antibiotice's main competitors?
Direct peers on record are Zentiva, Krka, Gedeon Richter, Polpharma and Alvogen. Broad incumbents are Stada Arzneimittel, Hikma Pharmaceuticals, Sandoz, Teva Pharmaceutical Industries and Viatris.
Does Antibiotice have an API?
No public API is recorded for Antibiotice.
What industry is Antibiotice in?
Antibiotice's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAC, Sterile Injectable Generics. Its NAICS code is 325412 and its SIC code is 2834.